Abstract
Preparations of the Cannabis sativa plant have been used to analgesic effect for millenia, but only in recent decades has the endogenous system responsible for these effects been described. The endocannabinoid (EC) system is now known to be one of the key endogenous systems regulating pain sensation, with modulatory actions at all stages of pain processing pathways. The EC system is composed of two main cannabinoid receptors (CB1 and CB2) and two main classes of endogenous ligands or endocannabinoids (ECs). The receptors have distinct expression profiles, with CB1 receptors found at presynaptic sites throughout the peripheral and central nervous systems (PNS and CNS, respectively), whilst CB2 receptor is found principally (but not exclusively) on immune cells. The endocannabinoid ligands are lipid neurotransmitters belonging to either the N-acyl ethanolamine (NAEs) class, e.g. anandamide (AEA), or the monoacylglycerol class, e.g. 2-arachidonoyl glycerol (2-AG). Both classes are short-acting transmitter substances, being synthesised on demand and with signalling rapidly terminated by specific enzymes. ECs acting at CB1 negatively regulate neurotransmission throughout the nervous system, whilst those acting at CB2 regulate the activity of CNS immune cells. Signalling through both of these receptor subtypes has a role in normal nociceptive processing and also in the development resolution of acute pain states. In this chapter, we describe the general features of the EC system as related to pain and nociception and discuss the wealth of preclinical and clinical data involving targeting the EC system with focus on two areas of particular promise: modulation of 2-AG signalling via specific enzyme inhibitors and the role of spinal CB2 in chronic pain states.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
1 Cannabinoids and the Endocannabinoid System
The Cannabis sativa plant contains over 100 bioactive lipid compounds, known as cannabinoids, which produce a plethora of physiological effects in humans including profound analgesia. However, due to the abuse potential and numerous additional undesirable effects, such as hypomotility (Adams and Martin 1996), deficits in executive function (Pattij et al. 2008), and memory consolidation (Hall and Solowij 1998), the use of cannabis for medicinal purposes has been restricted until recent times. During the 1960s, the major psychoactive component Δ9-tetrahydrocannabinol (Δ9-THC) was isolated (Mechoulam and Gaoni 1967), and study of its pharmacology began in earnest. Many years later, a membrane-bound, cannabinoid-sensitive receptor with high expression levels in the nervous system was isolated (Devane et al. 1988; Herkenham et al. 1991). This receptor is now known to form the basis of a key signalling pathway regulating neurotransmission throughout the nervous system, the endocannabinoid (EC) system. The EC system is composed of two G protein-coupled receptors (GPCRs) known as cannabinoid receptors 1 and 2 (CB1 and CB2), two families of lipids constituting the EC ligands, and the synthetic and metabolic enzymes which initiate and terminate EC signalling.
In comparison to classical neurotransmitter systems, the EC system possesses several unusual properties from which its key role in control of nociception is derived. Perhaps the most important of these features is the positioning of the EC signalling machinery at neuronal synapses in pain processing pathways (see Fig. 1). ECs are predominantly retrograde neurotransmitters, synthesised in the postsynaptic cell and released into the synapse to travel across and interact with receptors on the presynaptic cell (Katona et al. 1999; Egertova and Elphick 2000), resulting in an inhibition of neurotransmitter release (Freund et al. 2003). Since ECs are not stored in vesicles prior to release, but instead are produced through activity-driven “on-demand” synthesis following strong neuronal activation (Ohno-Shosaku et al. 2001; Wilson and Nicoll 2001) and/or activation of Gq-protein-coupled receptors (Katona and Freund 2012), their signalling is uniquely positioned to act as a brake on neuronal signalling in response to high activity. In pain pathways, this manifests as antinociception or analgesia. Additionally, in contrast to the single ligand-multiple receptor paradigm present in most classical neurotransmitter systems (e.g. glutamate, GABA, 5-HT, etc., Di Marzo and De Petrocellis 2012), the EC system possesses multiple ligands acting at just two major receptors, although the metabolites of these ECs seem to target multiple receptors (Sagar et al. 2012). Given that the tissue concentration of ECs, the size of the metabolic enzyme pool, and the expression levels of EC-sensitive receptors can all vary with changes in physiological and pathophysiological state, this property produces a dynamic lipid network capable of exquisite fine-tuning of cellular signalling (Alexander and Kendall 2007).
2 The Cannabinoid Receptors
The two known cannabinoid receptors have distinct expression patterns, which underlie their separate physiological roles. The CB1 receptor is found both in the periphery and central nervous system (CNS), although expression in the CNS is far greater. CB2, in contrast, is typically expressed predominantly by cells of the immune system, including glial cells of the CNS. However, more recent studies have demonstrated functional effects of CB2 receptor activity on neurones (Racz et al. 2008b; Burston et al. 2013).
The CB1 receptor is considered to be the most abundant GPCR in the CNS and is highly expressed in the neocortex, cerebellum, and limbic regions (Herkenham et al. 1990, 1991), but is also expressed in the peripheral nervous system (PNS). At peripheral and central terminals of nociceptive sensory nerves, CB1 gates the transduction of peripheral noxious stimuli into central neuronal pain signals (Guindon and Beaulieu 2006); at the level of the spinal cord, CB1 receptors can act to reduce or enhance propagation of pain signals to the brain (Sagar et al. 2010a, b; Pernia-Andrade et al. 2009; Woodhams et al. 2012), and those in nociception-associated higher brain regions, such as the periaqueductal grey matter (PAG) and the rostral ventromedial medulla (RVM), can initiate descending inhibition, or block descending facilitation, to the spinal cord nociceptive circuitry (Herkenham et al. 1991; Burns et al. 2007; Rea et al. 2007; Petrosino et al. 2007; Nadal et al. 2013; Martin et al. 1999). Interestingly, and of growing importance in pain research, CB1 is also highly expressed in the frontal–limbic brain circuits which are central to the affective/emotional aspects of pain in humans (Burns et al. 2007; Lee et al. 2013).
In line with its role in retrograde neurotransmission, CB1 is generally expressed presynaptically on axon terminals (Katona et al. 1999), where it is enriched in the perisynaptic zone (Nyíri et al. 2005), perfectly positioned to modulate the activity of the N- and P-/Q-type calcium channels which mediate neurotransmitter release. CB1 is negatively coupled to adenylate cyclase via Gi/o proteins, and thus its activation leads to inhibition of calcium channels, activation of potassium channels, and ultimately the reduction of neurotransmitter release (Pertwee 1997). At the circuit level, the net result of CB1 activity can be excitatory or inhibitory depending on the identity of the presynaptic cell and its location within the neural network. In addition to neuronal CB1, there is evidence of expression in B cells of the immune system (Graham et al. 2010; Pacher and Mechoulam 2011; Kaplan 2013) and also on glial cells of the CNS (Salio et al. 2002; Stella 2004, 2009; Navarrete and Araque 2008). Indeed, astroglial CB1 appears to have a pivotal role in both cannabinoid-mediated behaviour (Han et al. 2012) and EC-mediated plasticity (Min and Nevian 2012).
In contrast to the almost ubiquitous expression of CB1 in the nervous system, CB2 expression is thought to be confined to immune cells such as macrophages (Han et al. 2009), lymphocytes (Cencioni et al. 2010), and mast cells (Samson et al. 2003) in the periphery and astrocytes and microglia in the CNS (Alkaitis et al. 2010; Salio et al. 2002; Stella 2010). Activation of CB2 is inhibitory via Gi/o proteins, mediating the well-characterised anti-inflammatory effects of the ECs as well as having a role in anti-hyperalgesia in inflammatory pain states (Quartilho et al. 2003; Cabral and Griffin-Thomas 2009; Cabral et al. 2008; Khasabova et al. 2011; Ibrahim et al. 2006). There is a growing debate about the presence of functional CB2 receptors on some populations of neurons in the CNS (see commentary by Atwood and Mackie 2010), although at present this evidence remains controversial. Despite this restricted expression profile, CB2 plays an important role in pain signalling and may be of particular importance in the development of chronic pain states. This is discussed in more detail later in this chapter.
3 Endogenous Ligands: The Endocannabinoids
The ECs are lipid signalling molecules formed of two major groups: the N-acylethanolamines (NAEs) and the monoacylglycerols (MAGs). The most widely investigated are anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), respectively (structures shown in Fig. 1). Although AEA was discovered first (Devane et al. 1992), 2-AG is now thought to be the major synaptic EC ligand in nervous tissue, acting as a full agonist at both CB1 and CB2 (Sugiura et al. 2000), and present at far higher levels than AEA in brain tissue (Stella et al. 1997). In contrast, AEA is a partial agonist at both cannabinoid receptors, with a slight selectivity for CB1 over CB2, but also acts as a full agonist at the ion channel receptor transient receptor potential vanilloid 1 (TRPV1) at higher concentrations (Zygmunt et al. 1999; Ross 2003). As such, AEA can be considered an endocannabinoid/endovanilloid substance and may have a dual role in nociception, being antinociceptive at cannabinoid receptors and pronociceptive at TRPV1 (see Starowicz and Przewlocka 2012 for review).
4 Endocannabinoid Synthesis and Degradation
The major ECs have distinct synthetic and degradative pathways, with the localisation of the enzymatic machinery for each ligand determining its physiological effects. Importantly, both classes of ECs are enzymatically synthesised de novo from membrane phospholipid precursors and are rapidly metabolised by specific enzymes, providing clear targets for the pharmaceutical modulation of EC signalling. A schematic diagram of the actions of ECs at a generic neuronal synapse can be seen in Fig. 1. Synthesis of ECs is initiated either via sustained increases in intracellular calcium following intense stimulation of the cell or through the activation of several classes of GPCRs (Hu et al. 2014). Of particular note is the group 1 metabotropic glutamate receptor mGluR5, which is often located in the perisynaptic zone (Lujan et al. 1996), and has an established role in nociception (Radulovic and Tronson 2012; Hu et al. 2012).
2-AG synthesis proceeds via the production of diacylglycerol (DAG) species from membrane phospholipids by PLCβ; these are then metabolised by the enzymes diacylglycerol lipase-α and β (DAGLα and β) to form 2-AG (Bisogno et al. 2003). Notably, DAG acts as a signalling molecule in its own right, activating protein kinase C (PKC) (Stella et al. 1997)—an enzyme with well-established pronociceptive effects in pain pathways (Velazquez et al. 2007). Synthesis of 2-AG therefore also terminates DAG signalling. Monoacylglycerol lipase (MAGL) is the major metabolic enzyme for 2-AG (Dinh et al. 2002), responsible for 85 % of brain 2-AG hydrolysis, with minor contributions from αβ hydrolase domains 6 and 12 (ABHD6 and ABHD12) (Blankman et al. 2007). ABHD12 is highly expressed in microglia, whilst ABHD6 is postsynaptic and may therefore regulate the release of 2-AG (Savinainen et al. 2011).
Originally, a shared synthetic pathway for AEA and its congener lipids palmitoylethanolamine (PEA) and oleoylethanolamine (OEA) via the enzyme N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) was described (Di Marzo et al. 1994; Okamoto et al. 2004). However, NAPE-PLD null mice have normal brain levels of AEA (Leung et al. 2006), and additional synthetic pathways have since been identified (Simon and Cravatt 2006, 2008), calling into question the predominance of this pathway in vivo. At present, the mechanism responsible for the production of AEA in pain pathways has not been conclusively determined. The NAEs PEA and OEA do not directly interact with cannabinoid receptors and are thus not considered to be true ECs. PEA, however, does have antinociceptive and anti-inflammatory properties via interactions with members of the peroxisome proliferator-activated receptor family (D’Agostino et al. 2009; Lo Verme et al. 2005). The metabolism of AEA occurs predominantly via the enzyme fatty acid amide hydrolase (FAAH), although other metabolic pathways have been identified (reviewed in Ueda et al. 2013), and these alterative pathways may have physiological relevance under certain conditions. Of particular relevance is the hydrolysis of both AEA and 2-AG by cyclooxygenase 2 (COX2) (Glaser and Kaczocha 2010), a key enzyme in pain processing, which can produce pronociceptive prostamide EC metabolites (Sang et al. 2006, 2007).
5 The Endocannabinoid System and Pain
Systemic administration of cannabinoid receptor ligands is well known to produce analgesia in animal models of acute and chronic pain (Walker and Huang 2002). Despite the recent increase in use of medicinal marijuana, and the development of licensed cannabinoid drugs such as Sativex for multiple sclerosis (Garcia-Merino 2013), concerns remain over dependence, tolerance, and the cognitive side effects produced by these medications. The undesirable effects of cannabinoids are caused by the global activation of CNS CB1 receptors, and as a result research has focussed on presumed site-specific modulation of endogenous ligand activity or on effects at the non-psychotropic CB2 receptor. In the next sections, we will describe the differing contributions of ECs to acute nociception and the development of pathophysiological pain states in each physiological compartment: at the periphery, in the spinal cord, and in supraspinal regions. Particular emphasis will be placed on two promising areas of EC research, namely, the modulation of 2-AG signalling and the novel role of spinal CB2 receptors in chronic pain states.
5.1 The EC System and Peripheral Pain Processing
In the periphery, CB1 receptors localised on sensory afferent terminals gate the transduction of pain signals from noxious stimuli (Stander et al. 2005). These receptors have a significant contribution to cannabinoid-mediated analgesia, since their selective deletion in mice greatly reduces the efficacy of both locally and systemically administered cannabinoids in models of acute and chronic pain (Agarwal et al. 2007). Numerous studies have demonstrated antinociceptive efficacy of local administrations of both AEA (Guindon et al. 2006; Guindon and Beaulieu 2006) and 2-AG (Desroches et al. 2008; Guindon et al. 2007), and elevated peripheral tissue levels of both ECs have been detected in numerous preclinical models of inflammatory pain (Beaulieu et al. 2000; Maione et al. 2007), suggesting endogenous activity of the EC system. These effects are not solely mediated via neuronal CB1, since blocking CB1 and/or CB2 receptors prior to formalin administration increases nociceptive responses (Guindon et al. 2007). In fact, the antinociceptive effect of peripherally administered 2-AG on inflammatory pain has been described as mainly CB2 mediated (Guindon et al. 2007). The mechanism is likely multifaceted, involving inhibition of the production and release of proinflammatory and pronociceptive mediators such as reactive oxygen species (Hao et al. 2010) and cytokines (Cencioni et al. 2010) by peripheral immune cells and also the peripheral release of endogenous opioids (Ibrahim et al. 2005; Desroches et al. 2014a).
Since ECs are rapidly degraded in vivo, their effects are short-lived, and they are thus unsuitable for use as analgesics. However, the recent development of specific inhibitors of the major catabolic enzymes (MAGL and FAAH) has enabled researchers to prolong the effect of endogenously generated ECs. This is a very promising analgesic strategy, since ECs are specifically generated at sites of nociceptive activity, and such an approach may avoid the unwanted effects of global CB1 receptor agonism. Systemic administration of either MAGL inhibitors (Long et al. 2009a; Ignatowska-Jankowska et al. 2014; Kinsey et al. 2009, 2013; Bisogno et al. 2009) or FAAH inhibitors (Jayamanne et al. 2006; Chang et al. 2006; Lichtman et al. 2004; Kathuria et al. 2003; Fegley et al. 2005; Russo et al. 2007) has been shown to be antinociceptive in models of acute and chronic pain. Local effects of MAGL and FAAH inhibition are best studied in rodent models of inflammatory pain, in which peripheral administration of an irritant produces oedema and pain behaviour. The MAGL inhibitor JZL184 (Long et al. 2009a) effectively blocks the pain behaviour and thermal hypersensitivity induced by intra-plantar capsaicin administration (Spradley et al. 2010). Intra-plantar JZL184 administration also inhibits local MAGL activity, increases 2-AG tissue levels, and blocks pain behaviour in the formalin model through mechanisms involving both CB1 and CB2 (Guindon et al. 2011). Peripheral FAAH inhibition via intra-plantar URB597 reduced carrageenan-induced hyperalgesia (Jhaveri et al. 2008) and also ameliorates an electrophysiological marker of central sensitisation in rat spinal cord (Sagar et al. 2008). Unlike the actions of 2-AG, peripheral effects of AEA may not involve CB2. URB937, a peripherally restricted FAAH inhibitor which cannot cross the blood–brain barrier, blocks the hypersensitivity induced by both inflammation and peripheral nerve injury via a CB1 receptor-mediated mechanism (Clapper et al. 2010). Enhancing peripheral EC signalling also has potential in the relief of chronic pain states, since inhibition of MAGL or FAAH is antinociceptive via CB1 and CB2 in a rodent model of neuropathic pain (Desroches et al. 2014b).
5.2 The Spinal Endocannabinoid System and Acute Pain Processing
The dorsal horn of the spinal cord is a key region in the pain processing pathway, receiving and encoding sensory input from the periphery and integrating the descending modulatory signals from higher brain regions. Intrathecal administration of cannabinoids is antinociceptive (Welch and Stevens 1992), whilst blocking spinal CB1 receptors produces hyperalgesia in mice (Richardson et al. 1997) and enhances nociception-evoked firing of wide dynamic range (WDR) neurones (Chapman 1999). These data suggest a powerful regulatory role of EC signalling at this level of the pain pathway.
Although the nociceptive circuitry of the dorsal horn has yet to be fully described (Todd 2010), the expression pattern of the EC system within some of its key components has been mapped. CB1 receptors are highly expressed presynaptically on the central terminals of nociceptive primary afferents and on populations of excitatory interneurons within the dorsal horn (Hegyi et al. 2009). At these synapses, the 2-AG signalling machinery has a complementary expression pattern, with DAGLα present postsynaptically (Nyilas et al. 2009) and MAGL localised within presynaptic terminals (Horvath et al. 2014). In contrast, the localisation of AEA-related machinery in the nociceptive circuitry remains unclear (Hegyi et al. 2012).
The simplest picture arising from these data is that spinal 2-AG signalling initiated by excessive nociceptive activity negatively modulates nociceptive signalling via inhibiting the release of pronociceptive neurotransmitters from primary afferent terminals. Indeed, under naïve conditions, spinal administration of the MAGL inhibitor JZL184 selectively inhibits acute mechanically evoked nociceptive neurotransmission in a CB1-receptor-mediated manner in rats (Woodhams et al. 2012), whilst FAAH inhibition is ineffective (unpublished data from our group). However, CB1 is also expressed on inhibitory interneurons and glial cells (Hegyi et al. 2009), and spinal levels of both AEA and 2-AG are elevated in animal models of acute and chronic pain (Sagar et al. 2010a, b, 2012). Spinal administration of AEA (Welch et al. 1995) or elevation of spinal AEA via the FAAH inhibitor URB597 (Jhaveri et al. 2006) is also antinociceptive, suggesting AEA signalling is also important. Furthermore, pronociceptive actions of CB1 agonism on inhibitory interneurons have been described following severe noxious stimulation (Pernia-Andrade et al. 2009), suggesting that the effects of EC signalling vary depending upon the physiological context.
During sustained noxious stimulation, spinal 2-AG and AEA signalling is temporally segregated. Assessing spinal levels of ECs in the surgical incision model of a resolving pain state in rats has revealed a time course of changes (Alkaitis et al. 2010). In the hours following a peripheral surgical incision, no changes in spinal 2-AG are observed, but there was a marked decrease in AEA levels corresponding to maximal mechanical hypersensitivity, which returns to baseline as nociceptive behaviour subsides. In contrast, 2-AG levels increase at later time points, corresponding with glial cell activation, upregulation of CB2 receptors, and resolution of the pain state. These data suggest that reduced AEA signalling may be involved in the onset of a pain state, whilst enhanced 2-AG signalling may be involved in pain resolution. Targeting AEA signals during the onset of pain behaviour may therefore not be an effective analgesic strategy, but it may instead be possible to block the onset of hypersensitivity by prolonging the immediate effects of 2-AG. A preliminary report indicates that spinal administration of JZL184 after carrageenan administration is able to block WDR receptive field expansion, a correlate of central sensitisation, in rats (Woodhams et al. 2012).
5.3 A Novel Role of Spinal CB2 Receptors in Chronic Pain States
In persistent pain states, such as neuropathic pain resulting from peripheral nerve damage, central sensitisation leads to a reorganisation of spinal nociceptive circuitry and the development of hypersensitivity. This manifests as both hyperalgesia (excessive pain following a nociceptive stimulus) and allodynia (perception of a normally innocuous stimulus as painful), for which current analgesics are largely ineffective. It is in such chronic pain states that EC research has the greatest potential. Spinal EC signalling is significantly enhanced in models of neuropathic pain, with elevations of both cannabinoid receptors (Lim et al. 2003; Zhang et al. 2003) and ECs reported (Sagar et al. 2012). Given the role of spinal 2-AG signalling at CB2 receptors in resolution of pain states highlighted above (Alkaitis et al. 2010), targeting CB2 in chronic pain states is a novel area of research with great promise.
A number of studies have reported upregulation of CB2 receptor mRNA and protein in the spinal cord in models of neuropathic pain (see references in Sagar et al. 2012), and spinal administration of CB2 agonists attenuates both neuronal (Sagar et al. 2005) and behavioural (Romero-Sandoval et al. 2008a; Yamamoto et al. 2008) nociceptive responses. Interestingly, and in contrast to both mixed CB1 and CB2 agonists and selective CB1 agonists, activation of spinal CB2 receptors was not effective in control rats. Similarly, CB2 agonism alters spinal nociceptive neuronal activity in a model of osteoarthritic pain, but has no effect in control animals (Burston et al. 2013). These data suggest a pain state-specific role for this receptor. Specificity of CB2 agonists has been demonstrated by their lack of effect in CB2 knockout mice in these models (Yamamoto et al. 2008). However, there is some conflicting evidence in the literature, with a recent study reporting no effect of the CB2 agonists GW405833 and JWH-133 on mechanical allodynia in the chronic constriction injury (CCI) model of neuropathy (Brownjohn and Ashton 2012). This study also reported no elevation of CB2 at either the protein or mRNA level, in contrast to numerous other studies.
The majority of preclinical studies of neuropathic pain utilise ligation or severance of peripheral nerves to induce a chronic pain state, but painful neuropathy is also associated with disease states such as diabetes, or as a result of chemotherapy treatments (Windebank and Grisold 2008). The few studies modelling these more clinically relevant conditions have, however, revealed evidence of a role for spinal CB2 receptors in attenuating pain behaviour. In a model of chemotherapy-induced neuropathy, spinal administration of the pan cannabinoid receptor agonist WIN55, 212-2 reduced mechanical allodynia via CB1 and CB2 receptors (Rahn et al. 2007). Likewise, in the rat STZ model of diabetes and diabetic neuropathy, CB1 receptor is downregulated in nociceptive primary afferent fibres (Zhang et al. 2007), but systemic administration of WIN55, 212-2 is still able to produce significant antinociceptive effects (Doğrul et al. 2004; Ulugol et al. 2004).
Targeting CB2 may also be effective in other chronic pain states, such as osteoarthritis. Mice over-expressing the CB2 receptor develop less severe pain behaviour following intra-articular injection of monosodium iodoacetate, whilst mice lacking CB2 receptors show enhanced pain responses on the contralateral side, indicating a role of CB2 receptors in this pain state (La Porta et al. 2013). Additionally, we have recently demonstrated that spinal CB2 expression is elevated in a rat model of osteoarthritic pain and that chronic systemic administration of the CB2 agonist JWH-133 can block pain behaviour, whilst acute spinal administration attenuates mechanically evoked nociceptive neurotransmission (Burston et al. 2013). Moreover, we found that spinal CB2 mRNA expression was negatively correlated with (macroscopic) knee chondropathy in end-stage OA patients, suggesting that disease progression may lead to a decrease in CB2 receptor expression and a facilitation of spinal hyperexcitability in human OA.
5.4 CB2 Receptor Modulation of Spinal Immune Cell Function
CB2 is primarily expressed on glial cells of the CNS, and these cells are therefore most likely to mediate the effects of CB2 agonists in models of persistent pain. Studies of cultured microglial cells have revealed that 2-AG signalling via CB2 receptors inhibits microglial migration (Walter et al. 2003) and that CB2 agonists reduce both the activation and migration of cultured primary microglia challenged with bacterial lipopolysaccharide (Romero-Sandoval et al. 2009). In a unilateral spinal nerve transsection model of neuropathic pain, CB2 upregulation on spinal microglia and perivascular cells has been reported (Romero-Sandoval et al. 2008b), and spinal administration of the CB2 receptor agonist JWH015 reduced both mechanical hypersensitivity and markers of microglia activation in this model. CB2 receptors are upregulated on both microglia and astrocytes following spared nerve injury in mice, and chronic systemic administration of the CB2 agonist NESS400 reduces pain behaviour, astrogliosis, microglial activation, and levels of proinflammatory cytokines, whilst promoting levels of anti-inflammatory cytokines (Luongo et al. 2010).
Genetic manipulations in mice have revealed the likely function of upregulated CB2 to be in attenuating the development of central sensitisation. Mice lacking CB2 receptors have enhanced pain responses to sciatic nerve ligation compared to their wild-type littermates, including the development of hypersensitivity in the contralateral side (Racz et al. 2008b). These behavioural effects are accompanied by large increases in spinal glial cell activation, which can be significantly attenuated by over-expression of CB2 receptors. Activation of CB2 receptors can reduce the release of proinflammatory cytokines from glial cells, and this appears to be important in the analgesic mechanism. Neuropathy induces a large IFN-γ response in CB2 knockout mice, whilst deletion of both IFN-γ and CB2 blocks the development of neuropathy-induced pain behaviour (Racz et al. 2008a).
It should be noted that the role of CB2 in persistent pain states may not be restricted to immune cells, as there is some evidence for neuronal CB2 expression in the spinal cords of neuropathic (Racz et al. 2008b) and osteoarthritic animals (Burston et al. 2013). However, at the present time, a lack of specific tools to map the expression of this receptor has hampered efforts to conclusively demonstrate neuronal expression.
5.5 Supraspinal Sites of Action of the Endocannabinoids
At the supraspinal level, the EC system can influence ascending pain signals in the thalamus, descending modulatory signals in the brainstem, and the affective/emotional aspects of pain sensation through actions in frontal–limbic circuits. In the rat, direct microinjection of cannabinoid agonists into the thalamus, PAG, dorsal raphe nucleus, and RVM all produce antinociceptive effects in acute pain tests (Martin et al. 1995, 1996, 1999), which can be blocked via antagonism of CB1 (Lichtman et al. 1996). The involvement of ECs at these sites has been revealed by the release of AEA following electrical stimulation of the PAG or after peripheral inflammatory insult (Walker et al. 1999). PAG levels of AEA and 2-AG are also elevated in animal models of neuropathic pain (Petrosino et al. 2007), highlighting this area as a key region in the pain matrix. Prolonging AEA action in the PAG via inhibition of FAAH is antinociceptive in acute pain tests, although a biphasic effect suggests higher AEA concentrations can result in pronociceptive via actions at TRPV1 (Maione et al. 2006). The mechanism of action of ECs in the RVM has been revealed through electrophysiological studies. In vivo recordings from the RVM in rats demonstrated that cannabinoids inhibit the firing of ON cells, whilst promoting the firing of OFF cells (Meng and Johansen 2004). As their names suggest, these two cell types have opposing effects, with ON cells facilitating and OFF cells inhibiting nociceptive activity.
The PAG has excitatory projections to the RVM, and the action of AEA in this region is thought to be via disinhibition of PAG neurons, leading to activation of OFF cells in the RVM, and induction of descending inhibitory GABAergic signalling to the spinal cord (Vaughan et al. 1999, 2000). EC signalling in the PAG also mediates stress-induced analgesia (SIA), the well-characterised reduction in nociceptive responses observed following the presentation of an external environmental stressor. In animal studies, mice or rats exposed to mild electrical foot shock show reduced pain behaviour in a subsequent test of acute nociception (Hohmann et al. 2005). This effect is mediated by CB1 and accompanied by the release of both AEA and 2-AG in the PAG. The effect size of SIA can be augmented through the use of either FAAH or MAGL inhibitors (Suplita et al. 2005, 2006), though it should be noted the MAGL inhibitor utilised in this study has low efficacy and selectivity (Vandevoorde et al. 2007). More recent evidence suggests that the involvement of 2-AG in the dorsolateral PAG is critical and suggests a mechanism involving the activation of descending inhibitory pathways (Gregg et al. 2012). The link between stress and pain in humans is far more complex than in animal models, but recent clinical studies suggest it is no less important (Vachon-Presseau et al. 2013). Since the EC system is also strongly linked to anxiety/anxiolysis (reviewed in Mechoulam and Parker 2013), it seems highly likely that EC signalling will be involved in this interaction. Indeed, a recent report has demonstrated that impaired endocannabinoid signalling in the RVM underpins hyperresponsivity to noxious stimuli in the Wistar Kyoto rat, a strain with a heightened stress/anxiety profile (Rea et al. 2014).
One of the major unresolved issues in pain research is how to match the objectively measurable neuronal and behavioural nociceptive output of nociceptive responses, with the subjective, integrative experience of pain. Since non-human animals cannot report their internal states, and invasive electrophysiological recordings cannot be performed in humans, it has long seemed that this was a gap which could not be bridged. However, the advent of imaging techniques such as functional magnetic resonance imaging (fMRI) has allowed researchers to begin to address this. Cannabinoids alter affective or emotional states in humans via effects on the frontal–limbic circuitry, and this likely contributes to their analgesic effects. Dissociating the affective component from the somatosensory is complex, but a recent neuroimaging study has attempted to do so. Subjects were asked to rate the intensity of mechanically evoked allodynic responses following cutaneous capsaicin treatment, in the presence and absence of systemically administered Δ9-THC, whilst brain activity was monitored via fMRI (Lee et al. 2013). The cannabinoid treatment had no significant effect on scores of pain intensity, but reportedly reduced the unpleasantness of the pain sensation. This effect was accompanied by reduced activity in the anterior cingulate cortex (ACC) and enhanced activity in the amygdala. The ability of EC-directed perturbations to mimic this affective component of cannabinoid analgesia has not yet been tested, but this study indicates that this will be an important question to answer. Some recent preclinical data mirror these fMRI findings and further highlight the ACC as an important area in the aversive component of pain (Lu et al. 2011; Chen et al. 2012). Astrocyte activity in the ACC correlates with the maintenance of pain aversion behaviour, and ablation of these astrocytes reverses the behavioural phenotype. Since astrocyte activity is regulated by cannabinoid receptors, it seems logical to assume that altering EC tone within the ACC could prove a useful strategy for treating the affective component of chronic pain states.
5.6 Enhancing EC Signalling: Problems of Plasticity
The antinociceptive efficacy of 2-AG elevation via MAGL inhibition in preclinical models is well established, presenting a very promising area for therapeutic research. Systemic administration of the MAGL inhibitor JZL184 (Long et al. 2009a) elevates levels of 2-AG in brain and peripheral tissues (Long et al. 2009b) and increases acute pain thresholds in mice. Robust antinociceptive effects have also been demonstrated in models of peripheral inflammatory pain (Ghosh et al. 2013), gastrointestinal pain (Busquets-Garcia et al. 2011; Kinsey et al. 2011), neuropathic pain (Kinsey et al. 2009, 2010), chemotherapy-induced neuropathy (Guindon et al. 2013), and bone cancer pain (Khasabova et al. 2011). Many of these conditions are refractory to standard analgesics, and thus targeting MAGL/2-AG has great potential. However, some recent evidence suggests that there may be a problem with using MAGL inhibitors. High doses of JZL184 induce some cannabinoid-like behaviours (Long et al. 2009a), suggesting that this approach may not entirely avoid the unwanted side effects of cannabinoids. Worse still, sustained global elevation of 2-AG via genetic deletion of MAGL or persistent blockade of MAGL activity with JZL184 produces functional antagonism of the brain EC system, resulting in profound downregulation and desensitisation of CB1 receptors in nociception-associated regions and a loss of analgesic phenotype (Chanda et al. 2010; Schlosburg et al. 2010). Chronic JZL184 administration may also result in physical dependence since repeated high dose JZL184 treatment produces behavioural symptoms of withdrawal when precipitated with a CB1 antagonist (Schlosburg et al. 2009).
However, these may not be insurmountable problems. Chronic partial inhibition of MAGL produces sustained analgesia in the absence of cannabinoid side effects in mice (Busquets-Garcia et al. 2011; Kinsey et al. 2011). Furthermore, a novel inhibitor, KML129, with a more attractive therapeutic profile has been developed (Ignatowska-Jankowska et al. 2014). This compound has greater selectivity for MAGL over FAAH than JZL184 and produces antinociceptive, but not cannabimimetic, effects in mouse models of acute and chronic pain. It remains to be seen whether this compound will also avoid functional antagonism of the EC system upon chronic administration.
FAAH inhibitors are also robustly antinociceptive in models of acute and chronic pain (Jayamanne et al. 2006; Chang et al. 2006; Lichtman et al. 2004; Kathuria et al. 2003; Fegley et al. 2005; Russo et al. 2007) and appear to lack the cannabimimetic effects associated with MAGL inhibition (Schlosburg et al. 2010; Busquets-Garcia et al. 2011). Although there is a wealth of preclinical data to support the use of EC-targeted compounds in clinical pain trials, the only major attempt to date was a failure. Pfizer investigated the ability of a highly selective FAAH inhibitor, PF-04457845, to produce analgesia in an osteoarthritic patient population (Huggins et al. 2012). The drug treatment was well tolerated and produced significant elevations in circulating AEA, but no analgesic effect was observed. Some preclinical evidence suggests a loss of antinociceptive activity with chronic administration of a FAAH inhibitor (Okine et al. 2012), but it is also possible that the major analgesic effect of cannabinoids in humans is dissociative, rather than sensory (Lee et al. 2013), an effect which has not been demonstrated with FAAH or MAGL inhibitors. This perhaps highlights a limitation of current clinical trials of analgesics, which focus on the sensory analgesic profiles of novel compounds without assessing effects on the affective/emotional aspects of pain. Based on this rather disappointing failure of PF-04457845, it remains to be seen whether the highly promising findings from animal studies can be translated into the clinic.
6 Summary
The EC system is a critical regulator of nociceptive function, active at all levels of the pain processing pathways. It is also a highly plastic system, with altered expression and function occurring with switches in physiological state. A wealth of preclinical data suggests that pharmacological modulation of EC function via the use of specific enzyme inhibitors is an efficacious analgesic approach and may be of particular importance in chronic, refractory pain states. However, clinical research in this area is still at an early stage, and some initial setbacks introduce a note of caution.
Abbreviations
- 2-AG:
-
2-Arachidonoyl glycerol
- Δ9-THC:
-
Δ9-Tetrahydrocannabinol
- ABHD6:
-
αβ-Hydrolase domain 6
- ABHD12:
-
αβ-Hydrolase domain 12
- ACC:
-
Anterior cingulate cortex
- AEA:
-
Anandamide
- AM251:
-
A CB1 selective receptor inverse agonist/antagonist
- CB1 :
-
Cannabinoid type 1 receptor
- CB2 :
-
Cannabinoid type 2 receptor
- CCI:
-
Chronic constriction injury (neuropathic pain model)
- CNS:
-
Central nervous system
- DAGLα:
-
Diacylglycerol lipase-α
- DRG:
-
Dorsal root ganglia
- EC:
-
Endocannabinoid
- FAAH:
-
Fatty acid amide hydrolase
- fMRI:
-
Functional magnetic resonance imaging
- GPCR:
-
G protein-coupled receptor
- MAG:
-
Monoacylglycerol
- MAGL:
-
Monoacylglycerol lipase
- NAE:
-
N-acylethanolamine
- NAPE-PLD:
-
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D
- PAG:
-
Periaqueductal grey matter
- PKC:
-
Protein kinase C
- PNS:
-
Peripheral nervous system
- RVM:
-
Rostral ventromedial medulla
- SR144528:
-
A CB2 selective receptor antagonist
- TRPV1:
-
Transient receptor potential vanilloid 1
- WDR:
-
Wide dynamic range neuron; a class of spinal neuron with key involvement in the transduction of nociceptive input
References
Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614
Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870–879
Aguiar DC, Moreira FA, Terzian AL, Fogaca MV, Lisboa SF, Wotjak CT, Guimaraes FS (2014) Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels. Neurosci Biobehav Rev 46(Pt 3):418–428
Alexander SPH, Kendall DA (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152:602–623
Alkaitis MS, Solorzano C, Landry RP, Piomelli D, Deleo JA, Romero-Sandoval EA (2010) Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One 5:e10891
Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467–479
Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS (2000) Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396:85–92
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. J Cell Biol 163:463–468
Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, Razdan RK, Wiley JL, Di Marzo V (2009) Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4:946–950
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347–1356
Brownjohn PW, Ashton JC (2012) Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience 203:180–193
Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng W-S, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104:9800–9805
Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V (2013) Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 8:e80440
Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479–486
Cabral GA, Griffin-Thomas L (2009) Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11:e3
Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251
Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5:e8688
Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, Piesla MJ, Zhang M-Y, Bingham B, Uveges A, Kowal D, Garbe D, Kouranova EV, Ring RH, Bates B, Pangalos MN, Kennedy JD, Whiteside GT, Samad TA (2010) Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 78:996–1003
Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102–113
Chapman V (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127:1765–1767
Chen FL, Dong YL, Zhang ZJ, Cao DL, Xu J, Hui J, Zhu L, Gao YJ (2012) Activation of astrocytes in the anterior cingulate cortex contributes to the affective component of pain in an inflammatory pain model. Brain Res Bull 87:60–66
Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13:6
D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D (2009) Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 613:54–59
Desroches J, Guindon J, Lambert C, Beaulieu P (2008) Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155:913–924
Desroches J, Bouchard JF, Gendron L, Beaulieu P (2014a) Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 261:23–42
Desroches J, Charron S, Bouchard JF, Beaulieu P (2014b) Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB(1) and CB(2) receptors. Neuropharmacology 77:441–452
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol 34:605–613
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
Di Marzo V, De Petrocellis L (2012) Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 367:3216–3228
Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686–691
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99:10819–10824
Doğrul A, Gül H, Yildiz O, Bilgin F, Güzeldemir ME (2004) Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368:82–86
Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol 422:159–171
Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352–358
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83(3):1017–1066
Garcia-Merino A (2013) Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 13:9–13
Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, Lichtman AH (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92:498–505
Glaser ST, Kaczocha M (2010) Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J Pharmacol Exp Ther 335:380–388
Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M (2010) Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 23:25–34
Gregg LC, Jung K-M, Spradley JM, Nyilas R, Suplita RL, Zimmer A, Watanabe M, Mackie K, Katona IN, Piomelli D, Hohmann AG (2012) Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci 32:9457–9468
Guindon J, Beaulieu P (2006) Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50:814–823
Guindon J, Loverme J, De Lean A, Piomelli D, Beaulieu P (2006) Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol 550:68–77
Guindon J, Desroches J, Beaulieu P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150:693–701
Guindon J, Guijarro A, Piomelli D, Hohmann AG (2011) Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163:1464–1478
Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67:94–109
Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611–1616
Han KH, Lim S, Ryu J, Lee CW, Kim Y, Kang JH, Kang SS, Ahn YK, Park CS, Kim JJ (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 84:378–386
Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J, Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G, Zhang X (2012) Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148:1039–1050
Hao M-X, Jiang L-S, Fang N-Y, Pu J, Hu L-H, Shen L-H, Song W, He B (2010) The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J Lipid Res 51:2181–2190
Hegyi Z, Kis G, Holló K, Ledent C, Antal M (2009) Neuronal and glial localization of the cannabinoid-1 receptor in the superficial spinal dorsal horn of the rodent spinal cord. Eur J Neurosci 30:251–262
Hegyi Z, Holló K, Kis G, Mackie K, Antal M (2012) Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. Glia 60(9):1316–1329
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, Decosta BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936
Herkenham M, Lynn AB, Johnson MR, Melvin LS, Decosta BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat-brain—a quantitative in vitro autoradiographic study. J Neurosci 11:563–583
Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112
Horvath E, Woodhams SG, Nyilas R, Henstridge CM, Kano M, Sakimura K, Watanabe M, Katona I (2014) Heterogeneous presynaptic distribution of monoacylglycerol lipase, a multipotent regulator of nociceptive circuits in the mouse spinal cord. Eur J Neurosci 39:419–434
Hu JH, Yang L, Kammermeier PJ, Moore CG, Brakeman PR, Tu J, Yu S, Petralia RS, Li Z, Zhang PW, Park JM, Dong X, Xiao B, Worley PF (2012) Preso1 dynamically regulates group I metabotropic glutamate receptors. Nat Neurosci 15:836–844
Hu SS-J, Ho Y-C, Chiou L-C (2014) No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids. Eur J Neurosci 39:467–484
Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153:1837–1846
Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093–3098
Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP (2006) CB2 cannabinoid receptor mediation of antinociception. Pain 122:36–42
Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, Tao Q, O’Neal ST, Walentiny DM, Wiley JL, Cravatt BF, Lichtman AH (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171(6):1392–1407
Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281–288
Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26:13318–13327
Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SPH, Kendall DA, Barrett DA, Chapman V (2008) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55:85–93
Kaplan BLF (2013) The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 137:365–374
Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81
Katona I, Freund T (2012) Multiple functions of endocannabinoid signalling in the brain. Annu Rev Neurosci 35:529–558
Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544–4558
Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS (2011) Increasing 2-arachidonoyl glycerol signalling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 64:60–67
Kinsey SG, Long JZ, O’Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902–910
Kinsey SG, Long JZ, Cravatt BF, Lichtman AH (2010) Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11:1420–1428
Kinsey SG, Nomura DK, O’Neal ST, Long JZ, Mahadevan A, Cravatt BF, Grider JR, Lichtman AH (2011) Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338:795–802
Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH (2013) Repeated low dose administration of the monoacylglycerol lipase inhibitor JZL184 retains CB1 receptor mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345(3):492–501
La Porta C, Bura SA, Aracil-Fernandez A, Manzanares J, Maldonado R (2013) Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. Pain 154:160–174
Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134
Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720–4726
Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585–593
Lichtman A, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt B (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448
Lim G, Sung B, Ji RR, Mao J (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105:275–283
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19
Long JZ, Li WW, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF (2009a) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37–44
Long JZ, Nomura DK, Cravatt BF (2009b) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16:744–753
Lu Y, Zhu L, Gao YJ (2011) Pain-related aversion induces astrocytic reaction and proinflammatory cytokine expression in the anterior cingulate cortex in rats. Brain Res Bull 84:178–182
Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P (1996) Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci 8:1488–1500
Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, De Novellis V, Malcangio M, Maione S (2010) 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyraz ole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis 37:177–185
Maione S, Bisogno T, De Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316:969–982
Maione S, De Petrocellis L, De Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766–781
Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM (1995) An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56:2103–2109
Martin WJ, Hohmann AG, Walker JM (1996) Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16:6601–6611
Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237–242
Mechoulam R, Gaoni Y (1967) Absolute configuration of delta1-tetrahydrocannabinol major active constituent of hashish. Tetrahedron Lett 12:1109–1111
Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21–47
Meng ID, Johansen JP (2004) Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124:685–693
Min R, Nevian T (2012) Astrocyte signalling controls spike timing-dependent depression at neocortical synapses. Nat Neurosci 15:746–753
Nadal X, La Porta C, Andreea Bura S, Maldonadois R (2013) Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol 716(1–3):142
Navarrete M, Araque A (2008) Endocannabinoids mediate neuron-astrocyte communication. Neuron 57:883–893
Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I (2009) Molecular architecture of endocannabinoid signalling at nociceptive synapses mediating analgesia. Eur J Neurosci 29:1964–1978
Nyíri G, Cserép C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–822
Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729–738
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305
Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, Barrett DA, Kendall DA, Bennett AJ, Chapman V (2012) Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol 167:627–640
Pacher P, Mechoulam R (2011) Is lipid signalling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193–211
Pattij T, Wiskerke J, Schoffelmeer ANM (2008) Cannabinoid modulation of executive functions. Eur J Pharmacol 585:458–463
Pernia-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, Filitz J, Koppert W, Schuttler J, Ji G, Neugebauer V, Marsicano G, Lutz B, Vanegas H, Zeilhofer HU (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325:760–764
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
Petrosino S, Palazzo E, De Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415–422
Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955–960
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Bellora N (2008a) Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signalling during neuropathic pain. J Neurosci 28:12136–12145
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Manzanares J, Zimmer A, Maldonado R (2008b) Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28:12125–12135
Radulovic J, Tronson NC (2012) Preso1, mGluR5 and the machinery of pain. Nat Neurosci 15:805–807
Rahn EJ, Makriyannis A, Hohmann AG (2007) Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152:765–777
Rea K, Roche M, Finn DP (2007) Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152:633–648
Rea K, Olango WM, Okine BN, Madasu MK, Mcguire IC, Coyle K, Harhen B, Roche M, Finn DP (2014) Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 155:69–79
Richardson JD, Aanonsen L, Hargreaves KM (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3–R4
Romero-Sandoval A, Chai N, Nutile-Mcmenemy N, Deleo JA (2008a) A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 1219:116–126
Romero-Sandoval A, Nutile-Mcmenemy N, Deleo JA (2008b) Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108:722–734
Romero-Sandoval EA, Horvath R, Landry RP, Deleo JA (2009) Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 5:25
Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790–801
Russo R, Loverme J, La Rana G, Compton TR, Parrott JA, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236–242
Sagar DR, Kelly S, Millns PJ, O’Shaughnessey CT, Kendall DA, Chapman V (2005) Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22:371–379
Sagar DR, Kendall DA, Chapman V (2008) Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155(8):1297–1306
Sagar DR, Jhaveri M, Richardson D, Gray RA, De Lago E, Fernandez-Ruiz J, Barrett D, Kendall D, Chapman V (2010a) Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. Eur J Neurosci 31:8
Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SPH, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V (2010b) Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 62:3666–3676
Sagar DR, Burston JJ, Woodhams SG, Chapman V (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 367:3300–3311
Salio C, Fischer J, Franzoni MF, Conrath M (2002) Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience 110:755–764
Samson MT, Small-Howard A, Shimoda LMN, Koblan-Huberson M, Stokes AJ, Turner H (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170:4953–4962
Sang N, Zhang J, Chen C (2006) PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 572:735–745
Sang N, Zhang J, Chen C (2007) COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 102:1966–1977
Savinainen JR, Saario SM, Laitinen JT (2011) The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol 204:267–276
Schlosburg J, Carlson B, Ramesh D, Abdullah R, Long J, Cravatt B, Lichtman A (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11:342–352
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu Q-S, Lichtman AH, Cravatt BF (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113–1119
Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/β-hydrolase 4 in this pathway. J Biol Chem 281:26465–26472
Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283:9341–9349
Spradley JM, Guindon J, Hohmann AG (2010) Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62:249–258
Stander S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38:177–188
Starowicz K, Przewlocka B (2012) Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci 367:3286–3299
Stella N (2004) Cannabinoid signalling in glial cells. Glia 48:267–277
Stella N (2009) Endocannabinoid signalling in microglial cells. Neuropharmacology 56(Suppl 1):244–253
Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017–1030
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773–778
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605–612
Suplita RL, Farthing JN, Gutierrez T, Hohmann AG (2005) Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49:1201–1209
Suplita RL, Gutierrez T, Fegley D, Piomelli D, Hohmann AG (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50:372–379
Todd AJ (2010) Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 11:823–836
Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280(9):1874–1894
Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I (2004) The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371:167–170
Vachon-Presseau E, Martel M-O, Roy M, Caron E, Albouy GV, Marin M-F, Plante I, Sullivan MJ, Lupien SJ, Rainville P (2013) Acute stress contributes to individual differences in pain and pain-related brain activity in healthy and chronic pain patients. J Neurosci 33:6826–6833
Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ (2007) Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150:186–191
Vaughan CW, Mcgregor IS, Christie MJ (1999) Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127:935–940
Vaughan CW, Connor M, Bagley EE, Christie MJ (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57:288–295
Velazquez KT, Mohammad H, Sweitzer SM (2007) Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 55:578–589
Walker M, Huang S (2002) Cannabinoid analgesia. Pharmacol Ther 95:127–135
Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96:12198–12203
Walter L, Franklin A, Witting A, Wade C, Xie YH, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398–1405
Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10–18
Welch SP, Dunlow LD, Patrick GS, Razdan RK (1995) Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J Pharmacol Exp Ther 273:1235–1244
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592
Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46
Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SPH (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167:1609–1619
Yamamoto W, Mikami T, Iwamura H (2008) Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583:56–61
Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O’Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17:2750–2754
Zhang F, Hong S, Stone V, Smith PJW (2007) Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 323:508–515
Zygmunt PM, Petersson J, Andersson DA, Chuang HH, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457
Acknowledgements
D.S. and J.J.B. are funded by Arthritis Research UK Pain Centre funding (grant no. 18769).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Woodhams, S.G., Sagar, D.R., Burston, J.J., Chapman, V. (2015). The Role of the Endocannabinoid System in Pain. In: Schaible, HG. (eds) Pain Control. Handbook of Experimental Pharmacology, vol 227. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46450-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-662-46450-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46449-6
Online ISBN: 978-3-662-46450-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)